Supernus, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph J. Ciaffoni
- Full Time Employees
- 838
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 9715 Key West Avenue North Chesterfield MD United States 20850
- IPO Date
- May 1, 2012
- CIK
- 0001356576
- Website
- indivior.com
- Similar Companies
- Business
- Supernus Pharmaceuticals, Inc. (SUPN) develops and commercializes products for the treatment of central nervous system (CNS) disorders, epilepsy, and other neurological conditions. The company offers a portfolio of branded products including Trokendi XR (extended-release topiramate) for epilepsy and migraine prevention; Oxtellar XR (extended-release oxcarbazepine) for partial seizure treatment; Qudexy XR (extended-release topiramate) for epilepsy and migraine prophylaxis; and SPN-817, an investigational product in clinical development for treatment-resistant epilepsy. Additional pipeline candidates include SPN-830 (apomorphine infusion device for Parkinson's disease motor fluctuations) and SPN-820 (viloxazine extended-release for major depressive disorder), with research focused on novel formulations and delivery systems for CNS therapeutics. Supernus operates primarily in the United States, with headquarters in Rockville, Maryland, where it was founded in 2005. In recent developments, Supernus strengthened its epilepsy portfolio through the 2024 FDA approval and launch of a generic equivalent to Epidiolex (cannabidiol oral solution), expanding access to treatments for rare epilepsy syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. The company also advanced its pipeline with positive topline results from the Phase 3 trial of SPN-817 in mid-2025, supporting a New Drug Application submission planned for late 2025, and initiated a strategic collaboration with a leading device manufacturer for the SPN-830 infusion pump commercialization. No major acquisitions, funding rounds, or reorganizations have been reported in the last two years, allowing focus on organic growth and regulatory milestones in the competitive CNS pharmaceuticals segment targeting neurologists, epileptologists, and pediatric specialists.
Company News
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More
Why Indivior Pharmaceuticals Stock Topped the Market Today
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Supernus Announces Third Quarter 2026 Financial Results
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says Undervalued
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Rated “Hold” by Sell-Side Brokerages
Head-To-Head Contrast: Supernus Pharmaceuticals (NASDAQ:SUPN) and Shineco (NASDAQ:SISI)
Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals to Participate in September Investor Conferences